Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
ID: 360536Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$50K - $150K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/360536
Timeline
    Description

    The National Institutes of Health (NIH) is offering a grant opportunity titled "Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This funding aims to support innovative projects that develop technologies for analyzing and managing biospecimens in cancer research and clinical care, with a focus on proof-of-concept studies that demonstrate feasibility in areas such as cancer biology, early detection, and health disparities. The total estimated program funding is $4.7 million, with individual awards ranging from $50,000 to $150,000, and approximately 17 awards are expected to be made. Interested applicants can reach out to Dr. Kelly Crotty at Kelly.crotty@nih.gov or by phone at 240-255-0917 for further information, with applications due by April 10, 2026.

    Point(s) of Contact
    Kelly Crotty, Ph.D.
    (240) 255-0917
    Kelly.crotty@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the grant titled "Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)." This funding opportunity aims to support exploratory research projects that focus on the development and validation of innovative technologies designed to enhance the understanding of cancer biology, improve early detection, and address cancer health disparities. The program is part of the Innovative Molecular Analysis Technologies (IMAT) initiative and is particularly interested in projects that have overcome major feasibility gaps, as evidenced by preliminary data, but still require further validation for broader adoption in the research community. The total estimated funding for this program is $4.5 million, with individual awards ranging from $50,000 to $150,000, and a total of nine awards expected. Interested applicants can reach out to Dr. Kelly Crotty at Kelly.crotty@nih.gov or by phone at 240-255-0917 for further information. The application deadline is April 10, 2026, with awards anticipated to be made by December 1, 2026.
    Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)" aimed at advancing research in cancer biology and oncology through the application of nanotechnology. This initiative encourages proposals that address significant challenges in these fields by focusing on mechanistic studies of nanomaterial interactions with biological systems, rather than clinical applications. The program is particularly important for enhancing the understanding of nanoparticle delivery mechanisms and improving diagnostic technologies in cancer treatment. Interested applicants can apply for grants with a budget cap of $475,000 per year over a maximum project period of five years, with applications due by May 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-246.html.
    Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), aimed at supporting advanced pre-clinical research in nanotechnology-based cancer diagnostics and therapeutics. This initiative encourages innovative projects that utilize nanoparticle formulations or nano-devices to address significant clinical objectives in cancer treatment, with a focus on enhancing treatment efficacy through combination therapies and immunotherapy. Funding is available up to $475,000 annually for a maximum of four years, with applications accepted from eligible institutions including higher education entities, nonprofits, and government organizations. Interested applicants should refer to the detailed application process outlined on Grants.gov and the NIH ASSIST system, with key deadlines spanning from April 2025 to November 2027. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health, through the National Cancer Institute (NCI), is offering a funding opportunity titled "Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis" under the R01 Research Project Grant program. This initiative aims to support research projects that implement early phase clinical trials (Phases 0, I, and II) focused on cancer-targeted diagnostic and therapeutic interventions, aligning with the NCI's mission to advance cancer research. Eligible applicants include a diverse range of organizations such as colleges, nonprofits, and governmental entities, with a maximum project budget of $499,999 in direct costs per year and an award period not exceeding five years. Interested parties should note that applications are due by January 7, 2027, and can seek further information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-081.html.
    Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Research in Cancer Nanotechnology" (IRCN), aimed at supporting transformative research in cancer biology and oncology through the application of nanotechnology. This initiative encourages projects that address significant barriers in cancer research by focusing on mechanistic studies of nanomaterial interactions and the delivery of nanoparticles to cancer targets, although clinical translation of these interventions is not included in the scope. Eligible applicants include a diverse range of institutions, such as historically black colleges and universities, tribal colleges, and community-based organizations, with a maximum funding amount of $475,000 per year for up to five years. Interested parties should submit their applications by May 4, 2026, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the "Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research" (R21 Clinical Trial Not Allowed). This funding opportunity aims to enhance diversity among early-stage and junior investigators in cancer research, particularly from groups that are underrepresented in the biomedical, behavioral, clinical, and social sciences. The initiative encourages innovative studies in cancer biology, with a maximum funding amount of $275,000 available over a two-year period, and applications must demonstrate scientific merit and innovation. The application window opens on May 17, 2024, with the first awards expected to be made in June 2024; interested applicants can find more information and submission guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the National Cancer Institute (NCI) for investigator-initiated early phase clinical trials focused on cancer treatment and diagnosis, specifically under the R01 Research Project Grant mechanism (PAR-24-085). This initiative invites research proposals for Phase 0, I, and II clinical trials that align with the missions of various NCI programs, while explicitly excluding Phase III trials. The program aims to advance cancer research by assessing novel therapeutic and diagnostic interventions, improving imaging technologies, and exploring treatment combinations, with applications encouraged from a diverse range of eligible organizations, including educational institutions and non-profits. Interested applicants should note that the submission deadlines begin on January 5, 2024, with the opportunity closing on January 8, 2027. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-085.html.
    NCI Small Grants Program for Cancer Research (NCI Omnibus) (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the NCI Small Grants Program for Cancer Research (R03), aimed at supporting short-term cancer research projects that require limited resources. This funding opportunity encourages diverse research efforts, including pilot studies, secondary data analyses, and the development of research methodologies, with a maximum budget of $50,000 per year for projects lasting up to two years. The program is designed to address significant knowledge gaps in cancer research and is open to a wide range of applicants, including public, private, and foreign entities. Interested parties should note that the application period opens on January 24, 2025, with a submission deadline of February 24, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Exploratory Grants in Cancer Control through the R21 Clinical Trial Optional mechanism, aimed at advancing innovative research in cancer control. This funding opportunity encourages applications focused on behavioral modification, screening, and understanding the etiological factors of cancer, with the goal of developing novel methodologies and tools that can significantly impact population-based cancer research. Grants of up to $275,000 are available for projects lasting up to two years, with application deadlines beginning January 16, 2025, and continuing through 2028. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PA-25-253.html.
    Forecast to Publish a Funding Opportunity Announcement for Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at soliciting applications for the early-stage development of informatics technologies that enhance cancer research and management. This initiative, part of the National Cancer Institute's Informatics Technology for Cancer Research (ITCR) Program, seeks to support the creation and significant modification of tools that facilitate data acquisition, management, analysis, and dissemination across various cancer research domains, including biology, treatment, early detection, and health disparities. Interested small businesses are encouraged to develop innovative, user-friendly technologies that demonstrate potential impact on cancer research, with applications expected to be submitted after the NOFO is officially released. For further inquiries, potential applicants can contact Dr. Juli Klemm at juli.klemm@nih.gov or by phone at 202-853-7889, with the estimated synopsis post date set for August 29, 2025, and the anticipated award date in July 2026.